Enovis Corporation
ENOVHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeEnovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. Valued at $1.22B, ENOV is a small-cap name in its sector. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Market Cap
$1.22B
Beta
1.48
P/E (TTM)
—
P/E (Fwd)
5.95
EPS (TTM)
$-19.23
EPS (Fwd)
$3.54
ROE
-54.1%
ROA
1.2%
Cash
$12.6M
Total Debt
$1.37B
Free CF
$185.9M
52W Change
-35.9%
Annual Financials
Cash vs Debt
Where ENOV stands vs its 150-day and 200-day moving averages
As of the September 28, 2026 close, ENOV finished 22.31% below its 150-day moving average ($23.76) and 23.15% below its 200-day moving average ($24.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENOV overbought or oversold?
At the September 28, 2026 close, ENOV's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ENOV has $12.6M in cash with $1.37B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $185.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -54.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.56B (2022) to $2.25B (2025), reflecting a 44% increase over the period.
Enovis Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Enovis Corporation's trajectory.